** Shares of Neuren Pharmaceuticals NEU.AX soar as much as 3.8% to A$19.73, post their biggest intraday pct gain since Dec 5** Co says partner Acadia Pharmaceuticals ACAD.O received U.S. FDA approval for DAYBUE STIX (trofinetide) for oral solution** DAYBUE STIX is a powder formulation for treatment of Rett syndrome, a rare genetic disorder that affects brain development** Co receives royalties on net sales** YTD, shares up 57.6%

(Reporting by Nichiket Sunil in Bengaluru)

((Nichiket.Sunil@thomsonreuters.com))